{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T18:57:26Z","timestamp":1774724246900,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2002,10,17]],"date-time":"2002-10-17T00:00:00Z","timestamp":1034812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002The resistance of <jats:italic>Helicobacter pylori<\/jats:italic> to clarithromycin has become one of the primary reasons for eradication failure.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To compare the eradication rates of triple therapy using amoxicillin (A), clarithromycin (C) and rabeprazole (R) or lansoprazole (L) against clarithromycin\u2010sensitive and clarithromycin\u2010resistant strains.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Two hundred and ninety\u2010five patients were randomly divided into four groups and treated for 1\u2003week: 147 cases were treated with RAC, i.e. 49 cases with R20C400 (10\u2003mg R\u2003+\u2003750\u2003mg A\u2003+\u2003200\u2003mg C, twice daily), 48 cases with R40C400 (20\u2003mg R\u2003+\u2003750\u2003mg A\u2003+\u2003200\u2003mg C, twice daily) and 50 cases with R40C800 (20\u2003mg R\u2003+\u2003750\u2003mg A\u2003+\u2003400\u2003mg C, twice daily); 148 cases with treated with LAC (30\u2003mg L\u2003+\u2003750\u2003mg A\u2003+\u2003200\u2003mg C, twice daily).<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002According to intention\u2010to\u2010treat and per protocol analyses, the eradication rates were 88% and 91% with RAC and 78% and 81% with LAC; the eradication rates with R20C400, R40C400 and R40C800 were 94%, 81% and 86%, respectively, in the intention\u2010to\u2010treat analysis. In addition, the eradication rates for clarithromycin\u2010sensitive strains with RAC and LAC were 98% and 89%, respectively, and for clarithromycin\u2010resistant strains with RAC and LAC were 8.1% and 0%, respectively.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002The eradication rate was significantly higher with RAC than LAC. The eradication rate for clarithromycin\u2010resistant strains was low in both groups, and an improved eradication rate could not be achieved by changing the dose of clarithromycin or proton pump inhibitor.<\/jats:p>","DOI":"10.1046\/j.1365-2036.2002.01368.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:46:14Z","timestamp":1047354374000},"page":"1933-1938","source":"Crossref","is-referenced-by-count":72,"title":["Eradication rates of clarithromycin\u2010resistant <scp>Helicobacter pylori<\/scp> using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin"],"prefix":"10.1111","volume":"16","author":[{"given":"K.","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,17]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2001.00027.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00456-3"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(99)00051-5"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.2008.S61"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1572-0241.1998.455_t.x","article-title":"Clarithromycin\u2010resistant Helicobacter pylori in patients with duodenal ulcer in the United States","volume":"93","author":"Vakil N","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_7_2","first-page":"386","article-title":"Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin\u2014influence on treatment outcome","volume":"93","author":"Adamek RJ","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259747"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90504-5"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00373.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00418.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02347561"},{"key":"e_1_2_8_13_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing; Tenth Information Supplement (Aerobic Dilution) M100\u2010S10.","author":"National Committee for Clinical Laboratory Standards.","year":"2000"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-12-199812150-00006"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70017-2"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113959"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00022.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00840.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01108.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2001.00037.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00810.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005409310412"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2002.01368.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2002.01368.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2002.01368.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:10:58Z","timestamp":1697519458000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2002.01368.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,17]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1046\/j.1365-2036.2002.01368.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2002.01368.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,17]]}}}